Merck & Co. share price today

Name: Merck & Co. Share Price Today (NASDAQ: MRK) - Merck & Co. Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

(MRK)

Merck & Co. share price is $97.92 & ₹8,475.71 as on 18 Jan 2025, 2.30 'hrs' IST

$97.92

▲

-2.78

(-2.76%)

Market is closed - opens 8 PM, 21 Jan 2025

View live Merck & Co. share price in Dollar and Rupees. Guide to invest in Merck & Co. stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Merck & Co., along with analyst recommendations, forecasts, and comprehensive financials.

Merck & Co. share price movements

Today's Low: $97.92
Today's High: $100.30
$97.92
0.0%
Downside
Day's Volatility :2.37%
Upside
2.37%
52 Weeks Low: $94.48
52 Weeks High: $134.63
$97.92
3.51%
Downside
52 Weeks Volatility :29.82%
Upside
27.27%

Merck & Co. Returns

Period	Merck & Co. Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-8.18%	-7.4%	1.3%
6 Months	-21.27%	-5.2%	7.9%
1 Year	-18.01%	0.5%	14.9%
3 Years	24.22%	8.3%	26.9%

Merck & Co. Key Statistics

in dollars & INR

Previous Close	$100.7
Open	$100.47
Today's High	$100.3
Today's Low	$97.92
Market Capitalization	$247.7B
Today's Volume	$15.3M
52 Week High	$134.63
52 Week Low	$94.48
Revenue TTM	$63.2B
EBITDA	$22.9B
Earnings Per Share (EPS)	$4.78
PE Ratio	20.49
Dividend Yield	3.31%
Profit Margin	19.23%
Quarterly Earnings Growth YOY	-0.33%
Return On Equity TTM	28.33%

How to invest in Merck & Co. from India?

It is very easy for Indian residents to invest directly in Merck & Co. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Merck & Co. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Merck & Co. or MRK on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Merck & Co. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Merck & Co. shares which would translate to 0.009 fractional shares of Merck & Co. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Merck & Co., in just a few clicks!

Returns in Merck & Co. for Indian investors in Rupees

Investment Value

₹1,00,000

Merck & Co. investment value today

Current value as on today

₹86,110

Returns

₹13,890

(-13.89%)

Returns from Merck & Co. Stock

₹18,011 (-18.01%)

Dollar Returns

₹4,121 (+4.12%)

Indian investors sentiment towards Merck & Co.

-35.07%

Period: Oct 22, 2024 to Jan 20, 2025. Change in 30 Days versus previous period

Investment in Merck & Co. from India has reduced in the last 30 days as on Jan 21, 2025. -35.07% less purchase transactions for Merck & Co. in the last 30 days versus the previous period.

-20%

Period: Oct 22, 2024 to Jan 20, 2025. Change in 30 Days versus previous period

Search volume for Merck & Co. on INDmoney from India has reduced in the last 30 days as on Jan 21, 2025. -20% less investors are searching Merck & Co. in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Merck & Co.

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	21822	-773.81	0.50%
Axis Innovation Fund Direct Growth	2958	-31.03	0.21%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	3823	0.00	2.06%
Axis Growth Opportunities Fund Direct Growth	56526	-979.60	0.34%
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	43000	0.00	1.13%

Global Institutional Holdings in Merck & Co.

Vanguard Group Inc
9.88%
BlackRock Inc
8.38%
State Street Corp
4.71%
Wellington Management Company LLP
3.00%
Geode Capital Management, LLC
2.34%
FMR Inc
1.97%

Analyst Recommendation on Merck & Co.

Buy

87%Buy

12%Hold

0%Sell

Based on 31 Wall street analysts offering stock ratings for Merck & Co.(by analysts ranked 0 to 5 stars)

Based on 31 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Merck & Co.

What analysts predicted

Upside of 28.22%

Target:

$125.55

Current:

$97.92

Insights on Merck & Co.

Price Movement
In the last 7 days, MRK stock has moved down by -1.7%
Increasing Revenue
Merck & Co. Inc. has shown positive revenue growth over the last four quarters. Revenue increased from $14.63 billion to $16.65 billion, reflecting an average growth rate of 4.2% per quarter.
Decreasing Net Profit
Merck & Co. Inc. has experienced a decline in net profit over the last two quarters. The profit decreased from $5.45 billion to $3.15 billion, reflecting an average decrease of 42.1% per quarter.
MRK vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 15.5% return, outperforming this stock by 33.1%
MRK vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 198.6% return, outperforming this stock by 176.2%
Price to Sales
Merck & Co. Inc. has a Price-to-Sales (P/S) Ratio of 3.9, meaning that for every $1 of sales, investors are willing to pay $3.9. In comparison, Eli Lilly And Company has a much higher P/S Ratio of 16.0, indicating that investors are willing to pay $16.0 for every $1 of sales. This suggests that investors perceive Eli Lilly's sales to be more valuable compared to Merck's.

Merck & Co. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$42.3B	↑ 5.41%
Net Income	$6.2B	↑ 142.21%
Net Profit Margin	14.71%	↑ 8.31%

	FY19	Y/Y Change
Revenue	$46.8B	↑ 10.75%
Net Income	$9.8B	↑ 58.25%
Net Profit Margin	21.01%	↑ 6.3%

	FY20	Y/Y Change
Revenue	$41.5B	↓ 11.36%
Net Income	$7.1B	↓ 28.2%
Net Profit Margin	17.02%	↓ 3.99%

	FY21	Y/Y Change
Revenue	$48.7B	↑ 17.31%
Net Income	$13.0B	↑ 84.65%
Net Profit Margin	26.79%	↑ 9.77%

	FY22	Y/Y Change
Revenue	$59.3B	↑ 21.72%
Net Income	$14.5B	↑ 11.27%
Net Profit Margin	24.49%	↓ 2.3%

	FY23	Y/Y Change
Revenue	$60.1B	↑ 1.4%
Net Income	$365.0M	↓ 97.49%
Net Profit Margin	0.61%	↓ 23.88%

	Q2 FY23	Q/Q Change
Revenue	$15.0B	↑ 3.78%
Net Income	$-6.0B	↓ 311.8%
Net Profit Margin	-39.74%	↓ 59.21%

	Q3 FY23	Q/Q Change
Revenue	$16.0B	↑ 6.17%
Net Income	$4.7B	↓ 179.41%
Net Profit Margin	29.73%	↑ 69.47%

	Q4 FY23	Q/Q Change
Revenue	$14.6B	↓ 8.34%
Net Income	$-1.2B	↓ 125.84%
Net Profit Margin	-8.38%	↓ 38.11%

	Q1 FY24	Q/Q Change
Revenue	$15.8B	↑ 7.83%
Net Income	$4.8B	↓ 488.42%
Net Profit Margin	30.19%	↑ 38.57%

	Q2 FY24	Q/Q Change
Revenue	$16.2B	↑ 2.42%
Net Income	$5.5B	↑ 14.55%
Net Profit Margin	33.76%	↑ 3.57%

	Q3 FY24	Q/Q Change
Revenue	$16.7B	↑ 3.1%
Net Income	$3.2B	↓ 42.13%
Net Profit Margin	18.95%	↓ 14.81%

	FY18	Y/Y Change
Profit	$28.8B	↑ 5.26%

	FY19	Y/Y Change
Profit	$32.7B	↑ 13.7%

	FY20	Y/Y Change
Profit	$27.9B	↓ 14.75%

	FY21	Y/Y Change
Profit	$35.1B	↑ 25.73%

	FY22	Y/Y Change
Profit	$41.9B	↑ 19.37%

	FY23	Y/Y Change
Profit	$44.0B	↑ 5.06%

	Q2 FY23	Q/Q Change
Profit	$11.0B	↑ 4.26%

	Q3 FY23	Q/Q Change
Profit	$11.7B	↑ 6.24%

	Q4 FY23	Q/Q Change
Profit	$11.3B	↓ 3.49%

	Q1 FY24	Q/Q Change
Profit	$12.2B	↑ 8.37%

	Q2 FY24	Q/Q Change
Profit	$11.9B	↓ 3.04%

	Q3 FY24	Q/Q Change
Profit	$12.6B	↑ 6.02%

	FY18	Y/Y Change
Operating Cash Flow	$10.9B	↑ 69.41%
Investing Cash Flow	$4.3B	↑ 61.03%
Financing Cash Flow	$-13.2B	↑ 31.52%

	FY19	Y/Y Change
Operating Cash Flow	$13.4B	↑ 23.05%
Investing Cash Flow	$-2.6B	↓ 160.94%
Financing Cash Flow	$-8.9B	↓ 32.67%

	FY20	Y/Y Change
Operating Cash Flow	$10.3B	↓ 23.71%
Investing Cash Flow	$-9.4B	↑ 259.19%
Financing Cash Flow	$-2.8B	↓ 68.04%

	FY21	Y/Y Change
Operating Cash Flow	$14.1B	↑ 37.61%
Investing Cash Flow	$-16.6B	↑ 75.32%
Financing Cash Flow	$2.6B	↓ 191.56%

	FY22	Y/Y Change
Operating Cash Flow	$19.1B	↑ 35.34%
Investing Cash Flow	$-5.0B	↓ 70.04%
Financing Cash Flow	$-9.1B	↓ 451.68%

	FY23	Y/Y Change
Operating Cash Flow	$13.0B	↓ 31.89%
Investing Cash Flow	$-14.1B	↑ 183.93%
Financing Cash Flow	$-4.8B	↓ 47.25%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$3.7B	↑ 176.62%
Investing Cash Flow	$-11.4B	↑ 385.08%
Financing Cash Flow	$3.8B	↓ 282.96%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$7.7B	↑ 108.34%
Investing Cash Flow	$-334.0M	↓ 97.08%
Financing Cash Flow	$-4.3B	↓ 213.6%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$246.0M	↓ 96.81%
Investing Cash Flow	$53.0M	↓ 115.87%
Financing Cash Flow	$-2.2B	↓ 47.41%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$3.1B	↑ 1156.1%
Investing Cash Flow	$-1.4B	↓ 2696.23%
Financing Cash Flow	$-2.8B	↑ 25.35%

Merck & Co. Technicals Summary

Sell

Neutral

Buy

Merck & Co. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Merck & Co. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Merck & Co. Inc.	-1.46%	-21.27%	-18.01%	24.22%	10.57%
Eli Lilly And Company	-8.86%	-17.37%	15.03%	201.86%	413.93%
Johnson & Johnson	1.21%	-3.49%	-9.5%	-9.78%	-1.01%
Novo Nordisk A/s	-11.3%	-40.96%	-25.41%	64.9%	155.53%
Abbvie Inc	-3.83%	-0.92%	3.73%	29.81%	101.2%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Merck & Co. Inc.	20.49	20.49	0.07	7.69	0.28	0.11	0.03	17.58
Eli Lilly And Company	78.12	78.12	0.69	12.98	0.65	0.14	0.01	15.83
Johnson & Johnson	24.34	24.34	0.86	9.97	0.21	0.08	0.03	29.14
Novo Nordisk A/s	26.86	26.86	1.28	23.09	0.89	0.21	0.02	27.07
Abbvie Inc	59.78	59.78	0.41	10.75	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Merck & Co. Inc.	Buy	$247.7B	10.57%	20.49	19.23%
Eli Lilly And Company	Buy	$652.7B	413.93%	78.12	20.48%
Johnson & Johnson	Buy	$354.0B	-1.01%	24.34	16.74%
Novo Nordisk A/s	Buy	$352.9B	155.53%	26.86	35.01%
Abbvie Inc	Buy	$303.2B	101.2%	59.78	9.22%

Merck & Co. Dividend announcements

Merck & Co. Dividends December, 2024
In the quarter ending December,2024. Merck & Co. has declared dividend of $0.81
Read More

About Merck & Co.

Merck & Co., Inc. is an American multinational pharmaceutical company. The corporation conducts business outside of the United States and Canada under Merck Sharp & Dohme (MSD). It was founded as an American subsidiary of the German pharmaceutical company Merck & Co. in 1891. The company was given this name in honour of the Merck family. Merck acquired the Livogen trademark from Glaxo India for Rs 8 crore in 2000 - well over the market value. According to the company, Rofecoxib will be distributed in the Philippines via a co-marketing arrangement with the local pharmaceutical business Kopran. When Biochem Pharmaceutical Industries Ltd purchased Taloja in 2004, the firm spent a total of Rs 100 million, making it the most costly acquisition the company had made then. On March 27, 2002, a decision was made to rename the company from E Merck (India) Ltd to Merck Ltd, and the company was officially constituted on that day. This increased the firm's capacity for the manufacturing of Bulk Drugs by 33 tonnes in 2006, increasing the company's overall production capacity to 351 tonnes. In 2020, the pharmaceutical business will have six blockbuster medications or products with more than $1 billion in revenue. An antibody used to treat cancer is Keytruda, estimated to make $14.3 billion this year. Varivax is supposed to make $3.9 billion each, and Gardasil will make $1.4 billion each. Currently Merck & Co. Inc. has a market cap of $297.5 Billion. It has a P.E ratio of 21.66. The shares of Merck & Co. Inc. are trading at $97.92. .

Organization	Merck & Co.
Employees	70000
CEO	Mr. Robert M. Davis J.D.
Industry	Health Technology

Management People of Merck & Co.

Name	Title
Mr. Robert M. Davis J.D.	Chairman, President & CEO
Ms. Caroline Litchfield	Executive VP & CFO
Mr. Richard R. DeLuca Jr.	Executive VP & President of Merck Animal Health
Mr. Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division
Dr. Dean Y. Li M.D., Ph.D.	Executive VP & President of Merck Research Laboratories
Mr. Dalton E. Smart III	Senior VP of Finance, Principal Accounting Officer & Global Controller
Mr. David Michael Williams	Executive VP and Chief Information & Digital Officer
Mr. Peter Dannenbaum	Vice President of Investor Relations
Ms. Jennifer L. Zachary J.D.	Executive VP & General Counsel
Ms. Cristal N. Downing	Executive VP and Chief Communications & Public Affairs Officer

Important FAQs about investing in Merck & Co. from India :

What is Merck & Co. share price today?

Merck & Co. share price today stands at $97.92, Open: $100.47 ; Previous Close: $100.70 ; High: $100.30 ; Low: $97.92 ; 52 Week High: $134.63 ; 52 Week Low: $94.48. The stock opens at $100.47, after a previous close of $100.70. The stock reached a daily high of $100.30 and a low of $97.92, with a 52-week high of $134.63 and a 52-week low of $94.48.

Can Indians buy Merck & Co. shares?

Yes, Indians can invest in the Merck & Co. (MRK) from India.

With INDmoney, you can buy Merck & Co. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Merck & Co. at zero transaction cost.

How can I buy Merck & Co. shares from India?

It is very easy to buy Merck & Co. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Merck & Co. be purchased?

Yes, you can buy fractional shares of Merck & Co. with INDmoney app.

What are the documents required to start investing in Merck & Co. stocks?

To start investing in Merck & Co., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.